PCRX — Pacira Biosciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	430	542	667	675	701
Cost of Revenue
Gross Profit	312	401	468	490	531
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	391	452	607	604	767
Operating Profit	38.3	89.9	60	70.7	-65.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	20.1	56.4	13.3	61.7	-63.1
Provision for Income Taxes
Net Income After Taxes	146	42	15.9	42	-99.6
Net Income Before Extraordinary Items
Net Income	146	42	15.9	42	-99.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	146	42	15.9	46.1	-99.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.66	1.62	0.494	1.1	0.144